APR 12, 2018 10:30 AM PDT

The Genome in 3D: A Clinical Biomarker Platform

C.E. CREDITS: P.A.C.E. CE | Florida CE
  • Chief Scientific Officer, 3D Signatures Inc.
      Kevin has a passion for leading life sciences ventures through the creation of collaborative business ecosystems. Prior to his position at 3DS, Kevin worked as an independent consultant, offering strategic advisory services to help facilitate new life sciences collaborations for public and private sector clients. Kevin previously led the PERFORM Centre, a $36 Million health research and community services complex, as the Founding Chief Administrative Officer. There, he established and oversaw all operations across nine business units. Before returning to Canada to lead the start-up of the PERFORM Centre, Kevin spent several years leading the New Zealand government's economic development efforts to build strategic investment relationships across the biotechnology industry sector.

      Kevin holds a Bachelor of Science degree in Biology from the University of Victoria, and earned his Ph.D. in Experimental Medicine from McGill University, specializing in DNA repair and functional human genomics. During his Ph.D. studies, he was part of a biotech start-up developing clinical assays to map the functional organization of the human genome. Kevin went on to complete a postdoctoral fellowship in translational neuroscience and clinical gene therapy at the University of Auckland in New Zealand. Kevin is a Certified Strategic Alliance Professional.


    In genomics, as in life, you need to be in the right place at the right time, and you need integrity, to be credible. Since the availability of the human genome sequence, there's been an explosion in genetic testing. And epigenetics is entering the clinic by measuring chemical modifications to DNA or proteins that influence gene expression. Tumor mutational burden and microsatellite instability assessments are used to try and better match patients to the right therapies. But basic cell biologists have known for years that the genome has a dynamic organization in the cell which influences its expression also. And with genomic instability as the hallmark of cancer, this nuclear organization too can become disrupted in disease. Our group has developed a platform that captures and evaluates the content and configuration of the genome in individual cells, and are bringing it to the clinic. By combining immunohistochemistry with telomere-FISH labelling, three-dimensional microscopy, and proprietary TeloView(TM) software analytics, distinct profiles are identified that can distinguish between disease severity, risk of disease progression, and likelihood of response to therapy. This technology establishes the dynamic organization of the genome as a novel universal biomarker paradigm. This session will cover some of the fundamental principles of this new approach, and its applications already in cancer and Alzheimer's disease.

    Show Resources
    Loading Comments...